VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy

Bibliography

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Auerbach R, Kubai L, Knighton D, A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 1974;41:391-4
   PubMed Web of Science ®Google Scholar
• Folkman J, Klagsburn M. Angiogenic factors. Science 1987;235:442-7
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, Vascular endothelial growth factor is a secreted angiogenic molecule. Science 1989;246:1306-9
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5
   PubMed Web of Science ®Google Scholar
• Heldin CH, Wasteson A, Westermark B. Partial purification and characterization of platelet factors stimulating the multiplication of normal human glial cells. Exp Cell Res 1977;109(2):429-37
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor in induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
   PubMed Web of Science ®Google Scholar
• Fukumura D, Xavier R, Sugiura T. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94(6):715-25
   PubMed Web of Science ®Google Scholar
• Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-40
   PubMed Web of Science ®Google Scholar
• Tischer E, Mitchell R, Hartman T, The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266(18):11947-54
   PubMed Web of Science ®Google Scholar
• Millauer B, Wizigmann-Voos S, Schnurch H. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-46
   PubMed Web of Science ®Google Scholar
• Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272(51):32521-7
   PubMed Web of Science ®Google Scholar
• Dougher-Vermazen M, Hulmes JD, Böhlen P, Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF receptor. Biochem Biophys Res Commun 1994;205:728-38
   PubMed Web of Science ®Google Scholar
• Eliceiri BP, Paul R, Schwartzberg PL, Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-24
   PubMed Web of Science ®Google Scholar
• Jiang BH, Zheng JZ, Aoki M, Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000;97:1749-53
   PubMed Web of Science ®Google Scholar
• Henkemeyer M, Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 1995;377:695-701
   PubMed Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi TP, Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6
   PubMed Web of Science ®Google Scholar
• Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70
   PubMed Web of Science ®Google Scholar
• Autiero M, Waltenberger J, Communi D, Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43
   PubMed Web of Science ®Google Scholar
• Stalmans I, Ng YS, Rohan R, Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002;109(3):327-36
   PubMed Web of Science ®Google Scholar
• D'Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol 2007;171(1):1
   PubMedGoogle Scholar
• Grosskreutz CL, Anand-Apte B, Dupláa C, Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 1999;58(2):128-36
   PubMed Web of Science ®Google Scholar
• Couper LL, Bryant SR, Eldrup-Jorgenson J, Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1. Circ Res 1997;81:932-9
   PubMed Web of Science ®Google Scholar
• Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15(4):197-204
   PubMed Web of Science ®Google Scholar
• Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004;15(4):205-13
   PubMed Web of Science ®Google Scholar
• Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79(4):1283-316
   PubMed Web of Science ®Google Scholar
• Hwang RF, Yokoi K, Bucana CD, Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003;9(17):6534-44
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003111(9):1287-95
   PubMed Web of Science ®Google Scholar
• Sennino B, Falcón BL, McCauley D, Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007;67(15):7358-67
   Google Scholar
• Darland DC, Massingham LJ, Smith SR, Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003;264:275-88
   PubMed Web of Science ®Google Scholar
• Reinmuth N, Liu W, Jung YD, Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 2001;15:1239-41
   PubMed Web of Science ®Google Scholar
• Shih SC, Ju M, Liu N, Transforming growth factor ß1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc Natl Acad Sci 2003;100:15859-64
   PubMed Web of Science ®Google Scholar
• von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res 2006;312:623-9
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Methods in enzymology angiogenesis: in vivo systems, Part A. Volume 444, 2008, Chapter 2 Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules. Elsevier; 2008. p. 21-41
   Google Scholar
• Eliceiri BP, Paul R, Schwartzberg PL, Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-24
   PubMed Web of Science ®Google Scholar
• Alavi AS, Acevedo L, Min W, Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res 2007;6:2766-72
   Google Scholar
• Chen RR, Silva EA, Yuen WW, Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 2007;24(2):258-64
   PubMed Web of Science ®Google Scholar
• Levanon K, Varda-Bloom N, Greenberger S, Vascular wall maturation and prolonged angiogenic effect by endothelial-specific platelet-derived growth factor expression. Pathobiology 2006;73(3):149-58
   PubMed Web of Science ®Google Scholar
• Pietras K, Pahler J, Bergers G, Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008;5(1):e19
   PubMedGoogle Scholar
• Cao R, Brakenhielm E, Pawliuk R, Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9(5):604-13
   PubMed Web of Science ®Google Scholar
• Kano MR, Morishita Y, Iwata C, VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005;118(Pt 16):3759-68
   PubMed Web of Science ®Google Scholar
• Greenberg JI, Shields DJ, Barillas SG, A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008;456(7223):809-13
   PubMed Web of Science ®Google Scholar
• Gerhardt H, Golding M, Fruttiger M, VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161(6):1163-77
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res 1990;345A:317-30
   Google Scholar
• Abramsson A, Berlin O, Papayan H. Paulin, Shani M., and Betsholtz C.. Analysis of mural cell recruitment to tumor vessels. Circulation 2002;105(1):112-7
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40
   PubMedGoogle Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Padera TP, Stoll BR, Tooredman JB, Pathology: cancer cells compress intratumour vessels. Nature 2004;427(6976):695
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Hutson TE, Figlin RA, Kuhn JG, Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13:1084-96
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
   PubMed Web of Science ®Google Scholar
• Prewett M, Huber J, Li Y, Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59(20):5209-18
   PubMed Web of Science ®Google Scholar
• Hampton T. “Promiscuous” anticancer drugs that hit multiple targets may thwart resistance. J Am Med Assoc 2004;292:419-20
   PubMed Web of Science ®Google Scholar
• Hansen-Algenstaedt N, Stoll BR, Padera TP, Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000;60:4556-60
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7
   PubMed Web of Science ®Google Scholar
• Stockmann C, Doedens A, Weidemann A, Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008;456(7223):814-8
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105(8):15-24
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103(2):159-65
   PubMed Web of Science ®Google Scholar
• Winkler F, Kozin SV, Tong RT, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6(6):553-63
   PubMed Web of Science ®Google Scholar
• Dorafshar AH, Angle N, Bryer-Ash M, Vascular endothelial growth factor inhibits mitogen-induced vascular smooth muscle cell proliferation. J Surg Res 2003;114(2):179-86
   PubMed Web of Science ®Google Scholar
• Ryan HE, Poloni M, McNulty W, Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-5
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Miller KD, Sissons SE, The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61(8):3369-72
   PubMed Web of Science ®Google Scholar
• Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004;167(2):223-9
   PubMed Web of Science ®Google Scholar
• Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008;8(4):309-16
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL, Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13(13):3942-50
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-23
   PubMed Web of Science ®Google Scholar
• Ebos JML, Lee CR, Cruz-Munoz W, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15(3):232-9
   PubMed Web of Science ®Google Scholar
• Mazzone M, Dettori D, Leite de Oliveira R, Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136(5):839-51
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG, Biomarkers of response and resistance to antiangiogenic therapy. Nat Clin Pract Oncol 2006;3(12):693-7
   PubMedGoogle Scholar